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Abstract 
Renal involvement in systemic lupus erythematosus patients (SLE) is a severe 
disease manifestation characterized by various clinical and histopathological 
alterations. The revised ISN/RPN 2003 classification defines the subclasses of 
lupus nephritis (LN) according to their pathological glomerular patterns, which 
has a crucial impact on the prognosis and treatment options in LN patients. 
There are widely accepted therapeutic agents such as cyclophophamide, 
mycophenolate mofetil, azathioprine and corticosteroids available. Several trials 
tried to determine a gold standard for the induction and maintenance therapy in 
LN and the place of newer drugs, biologicals, is investigated. We review 
recently reported data on current treatment regimens in LN in particular in the 
context of the ISN/RPN 2003 classification. 
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Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease that is 
characterized by the production of autoantibodies to nuclear components.1 The 
inflammatory response triggered by in situ formation and/or deposition of 
immune complexes is thought to be responsible for the various clinical 
manifestations such as vasculitis, nephritis and skin involvement. Especially, 
renal involvement, i.c. lupus nephritis (LN), remains a frequent and severe 
manifestation of SLE. Renal involvement in SLE is still one of the strongest 
predictors for morbidity and mortality.2-4 Although over the last decades the 
therapeutic options for LN have increased leading to better results, the survival 
rate among patients with LN is still about 75 % after 15 years.2 
The underlying mechanisms in the pathogenesis of LN are still poorly 
understood. Numerous immunological abnormalities have been found to be 
associated with LN. However, which factors relate directly to renal inflammation 
remains unclear. Renal involvement in human SLE has often been considered 
as a classical immune complex induced glomerulonephritis (GN) due to 
deposition of preformed circulating immune complexes or binding of 
autoantibodies to glomerular antigens. Characteristic autoantibodies such as 
anti-dsDNA, but also antibodies with specifity for nucleosomes, Sm, histone, 
SS-A or SS-B have been found in kidney eluates from murine lupus models and 
from LN patients.5-7 Moreover, it has been demonstrated that anti-DNA 
antibodies can also interact with glomerular constituents such as endothelial 
cells, type IV collagen, α-actinin-4 and heparan sulfate supporting the 
hypothesis of an immune complex mediated disease.8;9 Together, this data 
provides further evidence that autoantibodies play a crucial role in the 
pathogenesis of LN. 
Therefore, B cells, as the source of antibodies, have been 
acknowledged as an important lymphocyte subset in the pathogenesis of SLE 
and LN in particular. Alterations of B cell numbers, activation status and function 
have been demonstrated. At first glance, B cells, being the source of auto-
antibodies, are regarded as the main actors in the immunological cascade 
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ending in organ injury. There is growing evidence that, besides autoantibody 
secretion, other functions of B cells such as antigen presenting capacity and 
cytokine production contribute to the development of SLE as well. Since the 
autoimmune response is autoantigen driven and T-cell dependent, also T cells 
are involved. For the interaction between B- and T-cells ligation of costimulatory 
molecules is necessary.10 The increased expression of costimulatory molecules 
on B- and T-cells in SLE suggested novel therapeutic targets.11;12 However, T-
cells do more than initiation of B-cell activation. They can exert effector cell 
function themselves. The presence of T-cells in renal biopsies of LN patients 
and their presence in urine during active renal disease, support their migratory 
abilities and potential pathogenic role.13;14 
Because of the described involved immunological mechanisms, the 
therapeutic regimens in SLE consist mainly of immunosuppressive drugs. 
Several therapeutic options are nowadays available to induce and maintain 
remission. However, therapy related toxicity is still a major concern in this, 
overall relatively young, patient group. This manuscript will review the current 
status of the therapeutic options in LN. 
 
Clinical features of lupus nephritis  
Renal manifestations in SLE are frequent and may vary from mild to severe. 
Almost 50-60 % of all SLE-patients develop glomerulonephritis during the 
course of their disease. Therefore, early detection and monitoring of renal 
involvement is crucial. Evaluation for LN includes dipstick and microscopic 
urinanalysis, urinary protein and creatinine excretion, determination of serum 
creatinine and serological markers such as anti-dsDNA antibody titres and C3 
and C4 levels. All of these parameters are taken into account when treatment is 
designed. Several studies examined the correlations of serological 
abnormalities with renal histology. Serum C3 and anti-dsDNA titers have been 
considered as valuable predictors.15-17 However, none of the clinical or 
serological parameters, either separately or in combination, can adequately 
predict the specific histological abnormalities and severity of the renal injury in 
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SLE patients. Therefore, a renal biopsy is mandatory. Thus, all patients 
suspected to have LN should undergo a renal biopsy, unless there are contra-
indications.  
Treatment of LN requires an understanding of the immunopathology. 
Therefore, we will briefly discuss the histopathological findings, which are 
characteristic for LN and are the basis for the ISN/RPS classification 
(Table 1).18 
 
ISN/RPS Classification of lupus nephritis (LN) (2003) 
class I minimal mesangial LN 
class II mesangial proliferative LN 
class III focal LN (<50 % of all glomeruli) 
class IV diffuse LN (>50 % of all glomeruli) 
class V membranous LN 
class VI advanced sclerosing LN 
 
Table 1. ISN/RPS classification of lupus nephritis (2003). 
 
 
Histopathology 
The histopathological findings are currently categorized by the ISN/RPS 
classification. The International Society of Nephrology (ISN) and the Renal 
Pathology Society (RPS) elaborated this classification in 2003 as a modification 
of the original WHO classification of 1974 (Table 1).18 The classification 
comprises six classes. The classification is based entirely on evaluation of 
glomerular alterations, although tubular, interstitial and vascular lesions are 
frequent findings in LN. Glomerular alterations are characterized by glomerular 
hypercellularity in the mesangial, endocapillary or extracapillary areas. Class I 
represents the mildest form of LN. Light microscopy reveals normal-appearing 
glomeruli, immunofluorescence microscopy however, shows mesangial immune 
deposits. Class II LN is defined as pure mesangial proliferation by light 
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microscopy. Additionally, subendothelial or subepithelial deposits can be visible 
by immunofluorescence or electron microscopy. If there are on light microscopy 
endo- and/or extracapillary alterations visible, LN has to be classified as Class 
III or IV depending on the severity and distribution. In Class III, the focal lesions 
are typically segmental and involve less than 50 % of glomeruli. Class IV is 
defined as diffuse segmental and/or global endocapillary and/or extracapillary 
glomerulonephritis affecting more than or equal to 50 % of the glomeruli. 
Furthermore is class IV subdivided into two categories to define whether the 
proliferative lesions are segmental (IV-S) or global (IV-G). If less than 50 % of 
the glomerular tuft is affected it is designated as IV-S and as IV-G if ≥50 % of 
the glomerular tuft is involved. Both class III and IV may have purely active (A), 
chronic (C) or mixed active and chronic lesions (A/C), which is indicated by the 
addition of the capital letters A and C. Class V defines membranous LN and 
simplifies the modified WHO classification of 1982 by eliminating the four 
confusing subclasses Va-Vd. Membranous LN can also be associated with 
Class III or Class IV. If so, both classes are mentioned (V+III or V+IV). If more 
than 90 % of glomeruli are sclerotic and without residual inflammatory activity, it 
is defined as Class VI.  
In order to evaluate LN more precisely, most investigators supplement 
the aforementioned ISN/RPS classification with a semiquantitative grading, 
developed at the National Institute of Health (NIH), to assess activity (potentially 
reversible lesions) and chronicity (irreversible lesions).19 These histological 
features, listed in Table 2, have to be graded on a scale of 0-3. Fibroid necrosis 
and cellular crescents are assigned double weight. The sum of all features 
evaluating the activity index yields a score of 0 to 24 and for the chronicity index 
a score of 0-12. Apart from the predictive value of these supplementary indices, 
the scoring of activity and chronicity provides important information about 
disease progression over time in case of sequential biopsies.20 
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Activity and Chronicity Index Activity 
 Index of Activity (0-24) 
Endocapillary hypercellularity 
Leukocyte infiltration 
Subendothelial hyaline deposits 
Fibrinoid necrosis/karyorrhexis* 
Cellular crescents* 
Interstitial inflammation 
Index of Chronicity (0-12) 
Glomerular sclerosis 
Fibrous crescents 
Tubular atrophy 
Interstitial fibrosis 
 
Table 2. The NIH scoring system for the activity and chronicity index is shown. Each item is graded 
on a scale of 0 – 3. The more severe lesions (*) are multiplied by 2. The sum of all features yields a 
score for the activity index between 0-24 and for the chronicity index between 0-12. 
 
The understanding of the classification of LN has a major impact on the analysis 
of past and present studies evaluating treatment strategies. Due to the 
heterogeneous nature of LN, most studies enroll a selective cohort of patients 
based on the histopathological findings. Therefore, the therapeutic options will 
be discussed for the different classes of LN.  
 
Immunosuppressive treatment of lupus nephritis 
Class I lupus nephritis 
In general there is no therapy necessary in patients with Class I LN in order to 
treat renal involvement (Figure 1). Administration of immunosuppressive 
regimens is dependent on extra-renal manifestations and disease activity. 
Patients should be monitored carefully and regularly to detect at an early stage 
transition to a more severe class of LN. 
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Class II lupus nephritis 
In patients with mesangial proliferative Class II LN corticosteroids might be 
administrated to prevent disease progression and development of a class III or 
IV LN. Along with supportive treatment such as ACE-inhibitors in patients with 
proteinuria (>1.0 g/24 h) and/or active urinary sediment, prednisone can be 
given (0.5 – 1 mg/kg/day, tapered to 0 over six months). Due to the lack of 
controlled studies, this recommendation is purely based on expert opinion. In 
addition, treatment with hydroxychloroquine can be considered.21 Also in 
patients with Class II LN, regular monitoring of disease activity and renal 
parameters is mandatory. 
 
Class III/IV lupus nephritis 
Class III and IV LN have several pathogenic and histopathological similarities 
and patients with these types of LN share a poor long term renal survival due to 
deterioration of kidney function. Therefore, clinical trials usually comprise both 
groups. The first therapeutic goal is to reduce disease activity and to restore 
renal function or to prevent deterioration. Therefore, an aggressive treatment 
strategy (corticosteroids and cytotoxic drugs), so called induction therapy, is 
necessary for a period of time between 6 and 24 months. After successful 
induction therapy, long-term maintenance therapy is advocated to prevent renal 
relapses.22  
 
Induction therapy 
As induction therapy high dose intravenous cyclophosphamide (ivCy) in 
combination with high dose prednisone dominated for years treatment of LN, 
since long-term outcome, especially in terms of preservation of renal function, 
was superior over treatment with prednisone alone.23;24 In these randomized 
controlled trials (RCTs) SLE patients received monthly for up to 6 months, and 
then every 3 month for another 18 months infusions of cyclophosphamide 
500 mg to 1000 mg per square meter (m2) of body surface. The occurrence of 
end-stage renal disease (ESRD) was significantly lower compared to patients 
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receiving oral prednisone alone (1.0 mg/kg body weight for 4-8 weeks, then 
tapered). Notably, this difference could only be detected after a follow up of at 
least 5 to 6 years. The survival rate did not differ between these groups in these 
studies. Nevertheless, these data demonstrated a beneficial effect of high dose 
ivCy on top of prednisone and this combination has been the gold standard for 
the therapy of proliferative LN for a long time. Patients with severe renal 
impairment (GFR<80 ml/min.) and/or >25 % of glomeruli affected by cellular 
crescents had a lower probability of doubling serum creatinine when treated 
with long-course ivCy (0.5-1.0 g/m2, every month for 6 months followed by 
quarterly pulses cyclophosphamide for 2 additional years) in comparison to 
intravenous methylprednisolone alone (1.0 g/m2).25  However, the use of ivCy 
resulted in high toxicity. Upper airway infections, herpes zoster infections and 
amenorrhea have been frequently reported.24  
The Euro-Lupus Nephritis Trial (ELNT) was initiated to test whether 
good long-term clinical results could also be achieved using lower doses of ivCy 
(6 pulses of 500 mg given at intervals of 2 weeks) versus a higher dose regimen 
(6 monthly pulses and 2 quarterly pulses with escalating doses, starting with 
500 mg, increased by 250 mg each course to maximum of 1500 mg per pulse), 
each of which was followed by azathioprine.26 Patients with biopsy proven 
proliferative glomerulonephritis (WHO class III, IV, Vc or Vd) were recruited 
between 1996 and 2000. After ten years follow-up there were no significant 
differences between the low dose and high dose regimen with regard to 
doubling of serum creatinin, ESRD and patient survival.  Of all patients (n=90) 
7 % had reached ESRD.27 Only 12 % reached sustained doubling of serum 
creatinine after this period of time. About 70 % of the patients randomised to the 
low dose arm did not receive any additional cyclophosphamide pulse during a 
10 year period. The low dose ivCy regimen had less toxicity. Thus, the low dose 
ivCy followed by AZA as maintenance treatment seems to be efficient and safe 
in Caucasian patients according to the ELNT.  
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Figure 1. Schematic view of currently recommended therapeutic regimens for the different classes 
of LN. All immunosuppressive regimens are accompanied with prednisone. The arrows represent 
responder (→) or non responder (-->). 
 
With respect to the acknowledged adverse effects of ivCy, especially 
associatedwith high dose regimens, other drugs have been studied as 
alternative induction regimens. The Dutch Working Party on SLE investigated 
the use of azathioprine (2mg/kg/day) combined with i.v. methylprednisone (MP) 
and low dose oral prednisone (initially 20 mg) in comparison to 
cyclophosphamide pulse therapy (750 mg/m2) in a RCT. In total 87 SLE-
patients with proliferative LN were included.28 The authors reported initially a 
similar efficacy regarding the proportion of patients that reached the primary 
end point (non-sustained doubling of initial serum creatinine). However, after a 
longer follow-up of 6.4 years doubling of serum creatinine (RR 5.2; CI: 1.1-25.2; 
p=0.04) and renal relapses (RR 4.9; CI: 1-6-15.0; p=0.06) occurred more 
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frequently in the AZA/MP arm. Furthermore, infectious events, especially 
herpes zoster infections, were more often seen in the AZA/MP arm.28 The 
clinical observation that the ivCy regimen is superior to AZA was supported by 
the histopathological assessment of renal biopsies obtained at study entry and 
after 2 years.29 The renal specimens of the patient receiving AZA/MP showed a 
more pronounced progression of chronic lesions than in the ivCy arm (p=0.05). 
Taken together, these studies show that the use of AZA/MP as induction 
therapy might be an option in selected patients, in particular women who do not 
accept the risk of infertility associated with ivCy. 
In recent years mycophenolate mofetil (MMF) was evaluated as 
induction therapy. Several studies analyzed MMF in comparison to 
cyclophosphamide as induction therapy in SLE patients with proliferative LN. 
One of the first was initiated by Chan et al. in 2000.30 The use of MMF (2 g/day) 
versus oral cyclophosphamide (2.5 mg/kg/day) followed by AZA was tested in 
42 SLE patients with diffuse proliferative LN (WHO class IV). Complete 
remission was reached in about 80 % of patients in both groups.  The 
proportion of patients which had a relapse or even treatment failure was similar 
in both groups. The authors concluded from their study that MMF in 
combination with prednisone is as effective as a regimen of oral Cy in 
combination with prednisone followed by AZA and prednisone. These 
comparable results persisted after a longer follow-up of 63 months.31 However, 
MMF was associated with fewer infections (p=0.013). Based on these results 
larger, open-labelled RCTs were performed. In a 24 week multicenter non-
inferiority trial, Ginzler el al. compared MMF (1000 mg/day, increased to 
3000 mg/day) with 4-weekly ivCy (500 mg/m2 of body surface area, increased 
to 1000 mg/m2).32 In contrast to the study of Chan et al. a large cohort of 140 
patients was recruited including patients with class III, class IV and class V LN. 
The primary endpoint was complete renal remission (CR) at week 24, defined 
as the return to within 10 % of normal values for serum creatinine, proteinuria 
and urinary sediment abnormalities. Due to the strict definition of CR, the 
proportion of patients which reached CR was low in both groups. However, it 
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was significantly higher in the MMF group (23 %) compared with the ivCy group 
(6 %, p=0.05). The studies by Chan et al. and Ginzler et al. raised the question 
whether MMF might even be superior to cyclophosphamide for the treatment of 
LN. To test this hypothesis a large study on behalf of the Aspreva Lupus 
Management Study Group, the ALMS study, has been performed.33 This study 
enrolled 370 patients with biopsy proven LN class III, class IV and V. The 
dosages of MMF and ivCy were similar to the aforementioned study of Ginzler 
et al. The primary endpoint in this study was a prespecified decrease in urine 
protein/creatinine ratio and stabilization (±25 % of baseline) or improvement in 
serum creatinine. Overall, the study failed to show superiority of MMF versus 
the ivCy regimen. About 56 % of patients responded to the MMF treatment in 
comparison to 53 % in the ivCy arm. Also the secondary endpoints (CR, 
systemic disease activity and safety) were similar in both groups. Remarkably, a 
subanalysis of the patients according to their racial background, revealed that 
those patients who were grouped as “others” (mostly blacks and mixed-race) 
showed a significantly better therapeutic response in the MMF arm (60.4 %) in 
comparison to ivCy (38.5 %, p=0.033). The other groups, Caucasian and Asian, 
respectively showed response rates between 53.2 % and 63.9 % but without 
statistically significant differences between MMF and ivCy. The difference 
between the Ginzler (percentage blacks 61 %) and the ALMS study (percentage 
blacks 26 %) therefore seems to be the ethnic composition of the studies. All in 
all, the Ginzler study indicated that MMF was more effective than ivCy with a 
more favourable safety profile and the ALMS study that MMF was equal to ivCy 
in induction of remission in LN. In 2008 Bao et al. reported a RCT in patients 
with LN class IV + V comparing tacrolimus (4 mg/day), and MMF (1000 mg/day) 
with monthly ivCy (750 mg/m2). Steroids were given in both arms (start 3 times 
500 mg methylprednisolon; thereafter 0.6-0.8 mg/kg with subsequent 
tapering).34 At 6 and 9 months CR in the tacro/MMF arm was 50 and 65 % 
respectively, while for the ivCy arm this was 5 and 15 %. Extrapolation of these 
results is hampered by the short follow-up of this study and the fact that only 
Chinese patients were included. 
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In conclusion, the currently available data show that MMF and ivCy have at 
least equal efficacy for the induction treatment of proliferative LN, but ivCy is 
associated with more severe adverse effects, particularly infections and 
infertility. Although MMF has obviously a more favourable profile, a final 
judgement has to be postponed until long-term data regarding MMF treatment 
become available. MMF seems to be the preferable therapy especially in blacks 
and young female patients with pregnancy wishes.35 However, MMF can not be 
used during pregnancy because of its teratogenic effects. Apart from these 
criteria, the therapy decision can be driven by several other factors such as 
patients’ compliance, drug intolerance or earlier treatment regimens. The choice 
for induction therapy in an individual patient should take into account all these 
aspects. 
 
Maintenance therapy 
The prevention of flares and renal relapses is the primary goal of maintenance 
therapy. Besides a frequent monitoring of the patient including assessment of 
renal parameters, the choice of long-term therapy is crucial. To achieve this 
goal ivCy seems to be an inadequate option because of the acknowledged side 
effects especially with increasing cumulative doses. Although, there is no clear 
consensus on the nomenclature “long-term” and subsequently no unequivocal 
recommendation can be given, cyclosporine A (CsA), AZA and MMF are the 
most preferable alternatives in combination with corticosteroids. A recent RCT 
comparing CsA (initial dose 4 mg/kg per day, reduced to a maintenance dose of 
2.5 to 3.0 mg/kg per day) and AZA demonstrated equal efficacy in the 
prevention of renal flares in a 24 months follow up for both regimens.36 
However, one should realize that CsA has less favourable side-effects including 
nephrotoxicity, hypertension and hyperlipidemia. Contreras et al. demonstrated 
in a cohort of 59 LN patients that MMF and AZA are more efficacious and safer 
than long-term therapy with ivCy.37 In this study major adverse events such as 
pneumonia, sepsis and meningitis have been reported in 25 % of the patients 
receiving ivCy maintenance therapy. This was significantly higher than in the 
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AZA group (p=0.01) and the MMF group (p=0.02), respectively. To assess 
which sequential regimen is superior two pivotal studies are under evaluation or 
still recruiting (MAINTAIN study, NCT00204022) and the maintenance results of 
ALMS. The results of these studies will elucidate how long and which dosages 
should be used in the maintenance regimen of proliferative lupus nephritis. 
Preliminary results from the MAINTAIN study (mainly Caucasian patients) report 
after a median follow-up for MMF of 48.4 months and for AZA of 54.3 months 
an equal efficacy of AZA and MMF with regard to time to flare, percentage of 
flares and doubling of serum creatinine.38 A recent meta-analysis reported no 
differences between MMF and AZA regarding the occurrence of relapses, renal 
failure and death.39 The incidence of proteinuric flares, changes in proteinuria 
and GFR were similar in the two treatment groups. In conclusion, at present 
AZA seems to be the best option for maintenance treatment of LN in Caucasian 
patients. It remains to be determined whether MMF is the best option for Afro-
Americans. Further results of the currently conducted studies are necessary to 
draw a final conclusion. 
There are hardly any data available on safety of discontinuation of 
immunosuppressive treatment in patients with proliferative LN. However, it 
seems arguable to taper immunosuppression slowly in patients who have been 
treated for at least 5 years and who have been serologically and clinically 
quiescent over a long period of time.22 
 
Class V lupus nephritis 
The prevalence of pure membranous glomerulopathy in SLE varies from 
approximately 10 to 40 % of cases of LN.40 Membranous LN has been a difficult 
entity to evaluate due to lower prevalences reported in the past. The lack of 
uniformity in the nomenclature also hampers analysis of the literature, in 
particular prior to 1982. Clinically, the majority of patients with membranous 
lupus nephropathy present with nephrotic-range proteinuria associated with 
edema.41;42 The characteristically young female population has an increased 
long-term risk for ESRD. Mercadal et al. observed after 20 years renal survival 
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in only 50 % of their patients with membranous LN.43 The optimal treatment for 
this entity has been controversial. A recent randomized, controlled trial of 
prednisone (Pred), intravenous cyclophosphamide (ivCy) or cyclosporine (CsA) 
by Austin et al. enrolled 42 patients with a median urinary protein excretion rate 
of 5.4 g/d.44 The authors reported proteinuria >5 g/d as best clinical baseline 
predictor associated with a decreased probability of reaching remission. The 
actual goal of this study was to analyze achievement of remission in the various 
treatment groups. At 1 year the cumulative probability of remission of 
proteinuria was 27 % in the prednisone group; 60 % with ivCY and 83 % with 
CsA. However, the difference between the ivCy and CsA treated patients was 
statistically not significant. All patients who achieved remission of proteinuria 
were subsequently treated with low-dose prednisone. Interestingly, although 
inducing remission with CsA was reasonable successful, in patients who were 
assigned to CsA significantly more often a relapse of the nephrotic syndrome 
occurred than in those who were assigned to the ivCy regimen. Remarkably, 
race and ethnicity was no independent predictor for remission. Recently, 
Rahakrishnan et al. analyzed 87 patients with class V lupus nephritis, who were 
enrolled in two studies, to assess the efficacy of mycophenolate (MMF) versus 
ivCy as induction therapy.32;33;42;45 Both arms, MMF and ivCy showed 
improvement of proteinuria, but no significant change of serum creatinine levels 
at 24 weeks. There was no difference between the MMF and ivCy group 
regarding percentual change of urinary protein excretion or serum creatinine. 
The analysis of this reasonable large patient cohort with pure class V LN 
suggests that both therapies have similar efficacy as induction therapy. 
However, the end-points were evaluated after 24 weeks. Long-term results are 
lacking so far which limits the strength of the conclusions.  
 Encouraging long-term results regarding the use of AZA as 
maintenance therapy in pure lupus membranous nephropathy have been 
reported by Mok et al.46 They observed in one-third of patients (13 out of 38) 
renal flares over a long period of 12 years. In summary, this study suggests 
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AZA in combination with prednisone as an effective, inexpensive and well-
tolerated maintenance therapy. 
 
Class VI lupus nephritis 
Class VI LN is characterized by irreversible scarring of renal tissue, without 
inflammatory activity. Therefore, patients suffering from class VI LN do not 
benefit from immunosuppressive treatment regimens and, unavoidable, will 
reach end-stage renal disease (ESRD). In the context of ESRD renal 
replacement therapies should be discussed such as dialysis or transplantation, 
as recently reviewed.47 
 
Supportive therapy 
Apart from the risk of progressive loss of renal function, various co-morbidities 
are associated with LN. Moreover, adverse effects due to therapeutic regimens 
contribute to an increased morbidity in LN patients. Therefore, the reduction of 
mortality and preservation of renal function remains an important aim. Initially, 
hydrochloroquine (HCQ) was mainly prescribed for patients with mild lupus 
manifestations (skin lesions; arthritis). However, a recent meta-analysis 
revealed that additional treatment with HCQ decreases disease activity; 
prevents flares; increases the probability of reaching a renal remission, 
improves survival, prevents irreversible organ damage and is safe and effective 
during pregnancy.21 Therefore, it seems justified to prescribe HCQ (400 
mg/day) as an adjunct treatment to all patients with LN, also in face of its low 
frequency of side-effects. 
Additionally, the reduction of mortality can be approached by several 
supportive therapeutic measures, which have been recently reviewed by 
Masood et al.48 Briefly, these therapies comprise medications controlling blood 
pressure, correcting dyslipidemia, preventing thomboembolic events and 
osteoporosis due to long-term therapy with corticosteroids.  
It is well accepted that SLE patients have an increased cardio-vascular 
risk and therefore blood pressure control is crucial.49;50 Blood pressure control 
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can be ideally achieved by the use of angiotensin-converting enzyme (ACE)-
inhibitors or angiotensin receptor blockers. ACE- inhibitors have been shown to 
reduce proteinuria and to delay occurrence of renal involvement of SLE-
patients.51 Moreover, hyperlipidaemia should be addressed as well. Less 
evidence is available for the prophylactic long-term anticoagulation of LN 
patients although nephritis itself is a risk factor for thrombosis.52 Anticoagulation 
with acetylsalicylic acid or acenocoumarol or warfarin should be considered if 
the renal biopsy demonstrates a thrombotic microangiopathy, which occurs 
most likely in the context of an antiphospholipid syndrome. However, RCT 
showing a beneficial effect of long term anticoagulation in LN are lacking so far. 
Furthermore, the prevention of osteopenia/osteoporosis due to corticosteroids 
should be addressed by the supplementation of vitamin D, calcium and in 
selected cases of bisphosphonates. In summary, there are several therapeutic 
approaches which have to be considered, beyond immunosuppression, to treat 
patients with LN adequately. 
 
Biologicals 
In contrast to the standard immunosuppressive drugs, novel treatments target 
specifically receptors to inhibit B- and T-cell interaction, to eliminate B-cells or  
cytokines influencing B- and T-cell activity and function.53 Several studies 
investigated experimental treatments including anti-CD20, anti-CD22, anti-BLyS 
(B lymphocyte stimulator), CTLA-4-Ig, and abetimus sodium (LJP-394) 
(Figure 2).  
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Figure 2:  This figure shows the hypothetical role for B- and T-cells for induction of glomerular 
inflammation in the pathogenesis of lupus nephritis (LN).  On the one hand decreased clearance of 
apoptotic cells can activate dendritic cells (DC) to trigger T-cell response (IL-17 production).On the 
other hand B- and T-cells activate each other by interaction and costimulation. Activated B-cells 
differentiated into plasmacells (PC) are able to produce auto-antibodies which subsequently form 
antigen/antibody complexes. Both, the antibodies as well as antigen antibody complexes can cause 
inflammation through deposition at the level of the glomerular basement membrane or bind to 
basement membrane constituents such as heparan sulfate. Activated effector T-cells might cause 
tissue injury as well. Chemokine receptors and activation markers enable them to migrate into the 
kidney. Several therapeutic interventions are illustrated by depletion of B cells, by regulation of B-
cell activity, by blocking costimulation and by elimination of circulating auto-antibodies.  
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Agents directed against B-cells specifically targeting CD20 
(rituximab/ocrelizumab) and CD22 (epratuzumab), have been investigated, 
since depletion or modulation of B-cells have been shown to be safe and 
effective in other autoimmune diseases than SLE.54-56  The fact that pathogenic 
autoantibodies in SLE are produced by B-cells raised the idea that depletion of 
B-cells might be beneficial. Additionally, case reports and single centre 
experience in LN patients refractory to standard immunosuppression provided 
encouraging results that indeed B-cell depletion might be effective in the 
treatment of LN.56 However, the results of the first RCT were disappointing. In 
the LUNAR study patients with LN (class III or IV) were randomized for 
rituximab (1000 mg at day 1, 15, 168 and 182) or placebo which was given on 
top of standard of care treatment, being MMF (1500 mg twice daily) and oral 
prednisone (60 mg initially, with subsequent tapering).57 In both arms 72 
patients were included. There were no differences in CR or partial remission 
between both groups (p = 0.55). The only significant difference in rituximab 
treated patients was a larger decrease in anti-dsDNA titers and a more 
pronounced increase in C3 levels. So, in patients with proliferative LN, addition 
of rituximab to induction therapy with MMF did not provide better (short-term) 
results. 
The BELONG (NCT00626197) study enrolled SLE patients with biospsy 
proven class III and IV LN to evaluate whether the addition of the humanized 
anti-CD20 antibody (ocrelizumab) to standard immunosuppressive care did 
provide additional benefit. This study was stopped prematurely because of an 
increased incidence of opportunistic infections. More promising results have 
been obtained by Dörner et al. who have demonstrated, in an open-label study, 
comprising 14 lupus patients, improvement of disease activity after 
epratuzumab (humanized anti-CD22).58 In addition to CD20, CD22 is another B-
cell restricted receptor, mainly expressed on premature and mature B-cells, but 
absent on plasma cells. Epratuzumab probably acts via modulation of the B-cell 
receptor (BCR) and partially through B-cell depletion, but the exact mechanism 
is unknown so far. In the study by Dörner et al. the administration of 4 
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consecutive weekly doses of 360 mg/m2 epratuzumab in SLE patients resulted 
in clinical improvement as assessed by the BILAG score. Larger trials, 
confirming these preliminary, data especially with respect to LN, are lacking so 
far. 
The impact of B- and T-cell interaction via costimulation is well known. 
CTLA4Ig is homologue to CD28 and binds to CD80/CD86 with high affinity. 
Infusion of CTLA4Ig obviously results in downregulation of B cell activity by 
blocking the CD28–CD80/CD86 pathway. In human trials CTLA4Ig (abatacept) 
has been successfully evaluated in rheumatoid arthritis.59 Results of controlled 
studies in patients with SLE are currently not available, but are ongoing. A 
phase-II multicenter trial (NCT00774852, ACCESS study) will evaluate the 
additional effect of abatacept to the ELNT regimen in LN patients. A benefical 
effect might be expected, as high levels of co-stimulatory molecules, especially 
CD80 and CD86 on B cells, were also found in human SLE.11;60 In a murine LN 
model, synergistic effects of abatacept with ivCy have been demonstrated.61 
Furthermore, expression of CD134L has been shown to be up-regulated in 
proliferative LN, suggesting a role for the CD134–CD134L pathway in its 
pathogenesis. CD134 expression was correlated with disease activity and 
associated with renal involvement in human SLE.12;62 A current study in BxBS 
mice demonstrated that blocking this interaction could be an effective 
alternative target to attenuate LN.63 This could be a promising future therapeutic 
target in LN. An antagonist against CD154 (CD40L) has been examined as a 
possible therapeutic approach in human LN. But short-term administration of 
anti-CD154 was associated with increased thrombosis, despite initial 
encouraging data about serology and renal function.64   
Beside the elimination/modulation of B-cells, also biologicals targeting 
anti-dsDNA antibodies directly have been investigated. There is substantial 
evidence that anti-dsDNA antibodies are involved in the pathogenesis of LN. 
Abetimus sodium (LJP-394) is a synthetic biological agent which is composed 
of four double stranded oligonucleotides linked to a non immunogenic 
polyethylene glycol platform. The ratio to use this construct was either as an 
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antagonist for the B cell receptor for DNA or as a decoy-antigen for anti-dsDNA 
antibodies.  Intravenous administration of abetimus results in a rapid reduction 
of circulating anti-dsDNA antibody titres.65;66 Cardiel et al. investigated whether 
treatment with abetimus (100 mg/week) for up to 22 months versus placebo 
could delay renal flares in a cohort of 317 patients. The authors reported a trend 
in several renal endpoints such as 25 % fewer renal flares in the abetimus arm, 
but there was no significantly prolonged time to renal flares in these patients.67  
Regulators of B cell activity such as B lymphocyte stimulator (BLyS) 
have also been investigated in SLE since elevated serum levels of BLyS have 
been detected in murine SLE models (MRL/Mp-lpr/lpr). In this lupus model serum 
levels of BLyS seem to be associated with  kidney damage whereas treatment 
with soluble BLyS receptor significantly prolonged survival of lupus mice.68 
Belimumab is a fully humanized IgG1 monoclonal antibody that binds to soluble 
human BLyS and inhibits its biologic activity. First results of a phase II trial in 
SLE patients showed a no beneficial effect of administration belimumab in 
combination with standard of care medication (SOC) in comparison with SOC 
alone.69 The role of belimumab in LN has still to be elucidated. 
Until now, all these agents had no additional beneficial effects in 
comparison to the “standard of care” immunosuppressive treatment. The lack of 
data from larger cohorts and long-term follow-up of RCTs hamper the 
interpretation of the currently available data. Until now there are no data to 
propagate the standard use of biologicals for induction therapy, but they might 
be an alternative option in LN patients resistant to other immunosuppressives. 
This recommendation is based on good results of rituximab therapy reported in 
(large) case-series of patients with (refractory) LN.70-72 The effect of rituximab in 
the LUNAR study might have gone unnoticed due to the relative mild to 
moderate lupus disease activity in the patients included. Furthermore, standard 
of care immunosuppressions is apparently sufficient in the majority of patients. 
The beneficial effects of rituximab become clear in those patients who have 
failed on other immunosuppressives. Besides this study design, which reduced 
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the power of the study to detect  a favourable response to rituximab in LN, long-
term data are necessary.73  
 
Expert Commentary & Five-year view 
In the last decade many studies provided useful information contributing to a 
better insight into the pathogenesis of SLE and to improvement of therapy. 
Current treatments appear to be relatively safe and efficacious in a large 
proportion of SLE patients. However, LN remains a difficult entity among SLE 
manifestations and therefore the therapeutic regimens are more complex and 
more toxic. Long term follow-up data are mandatory to define successful 
responses to treatment and to detect of possible long term adverse effects. 
Long-term data are available at least for the induction therapy with AZA/MP 
(Dutch Lupus Nephritis Trial) and low dose ivCy in proliferative LN (EURO-
Lupus trial). Additionally, initial results of alternative induction therapies i.e. with 
MMF are promising (ALMS-study), but long-term data are essential and can be 
expected within the next years. On the basis of these studies the following 
conclusions can be drawn so far:  
• for Caucasian patients low dose ivCY (6x500 mg, fortnightly) is an 
effective induction treatment 
• MMF (2x 1.5 g/day) seems to be an alternative induction treatment, 
especially for black patients. However, one should realize that long-
term data are lacking. 
• In patients with severe LN (severe renal impairment/high prevalence of 
glomerular crescents) high dose IVCY might still be option. 
For maintenance treatment limited data are available. Preliminary data of the 
MAINTAIN study have been published, but final analysis is still pending and can 
be expected by the end of this year. These data indicate that maintenance 
treatment with AZA is equal effective as MMF. More difficult remains the 
interpretation of studies investigating the use of biologicals. This growing group 
of highly specific immuno-modulators has been studied in addition to standard 
of care treatment. Recently, RCTs have been performed for anti-CD20 
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therapies, but other biologicals have been evaluated with other study designs. 
Therefore, within the next years RCTs including larger cohorts of patients will be 
initiated. So far data indicate that addition of these biologicals to standard care 
immunosuppression does not provide additional benefit in induction treatment of 
proliferative lupus nephritis. With the current status of knowledge it should be 
reserved for cases refractory to treatment with standard care 
immunosuppressives. Moreover, in severe refractory LN and life threatening 
lupus immunoablative chemotherapy followed by autologous hemopoietic stem 
cell transplantation might be considered. Limited single center experience 
showed long-term remission in 5/7 patients. On the other hand this extensive 
treatment was associated with a mortality rate of almost 30 %.74 A less harmful 
result has been obtained by allogeneic mesenchymal stem cell transplantation 
(MSCT) in refractory SLE.75 In a cohort of 15 SLE patients with persistently 
active disease a significant reduction in SLEDAI (from 12.2 to 3.2, at 12-month 
follow-up) and proteinuria (from 2.5 to 0.85 g/24 h) was shown. Similar results 
have been reported by Sun et al. with umbilical cord-derived MSCs in 16 
refractory SLE patients.76 At present, these regimens remain experimental, but 
several RCTs evaluating the effect of transplanting autologous or mesenchymal 
stem cells in SLE patients, are currently carried out.  
In conclusion, recent studies have indicated that long-term use of high 
doses of ivCY are not the first choice treatment option for proliferative lupus 
nephritis. Low dose ivCY or MMF are now the first options.  Long-term data on 
induction and maintenance treatment will help to define therapeutic decisions 
more precisely. Moreover, at this moment the various biologicals do not provide 
extra benefit over the current standard of care. A more precise definition of 
patients who will benefit from those biologicals, could establish tailor-made 
therapy. Especially, in cases of refractory LN this new generation of medication 
will become a valuable alternative option. 
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Key Issues 
• Lupus nephritis (LN) is a severe manifestation of systemic lupus 
erythematosus which should be confirmed by a renal biopsy  
• LN is classified according to the ISN/RPS classification which 
comprises six classes (I-VI) 
• The induction regimen of class III and IV LN includes ivCy (Eurolupus) 
or MMF in combination with prednisone. The maintenance therapy 
preferably consists of AZA with prednisone. MMF or CsA might be 
considered as alternatives whenever AZA is not tolerated. 
• Class V LN can be treated with MMF, CsA or ivCy, respectively. The 
level of initial proteinuria is a good predictor of renal response to 
treatment. 
• The use of biological agents (rituximab) has shown only beneficial 
effects for selected patients with refractory class III/IV LN  
• Supportive care, including use of hydroxychloroquine, is mandatory to 
further decrease morbidity and mortality in LN patients. 
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